The company is collaborating with CPESN USA to bring more services to customers at independent pharmacies across the country.

The latest news for pharma industry insiders.

Joint venture expected to utilize Degron’s GlueXplorer platform to identify, validate, and optimize molecular glue degraders.

Cityblock is partnering with Sunshine Health in Florida.

The latest news for pharma industry insiders.

Approval for the Phase III protocol of LAE002 Plus LAE001 come as a result of posiive Phase II data, which showed promising benefits for metastatic castration-resistant prostate cancer (mCRPC) patients.

Under terms of the agreement, Nona Biosciences is expected to receive an upfront payment of $19 million, with the potential of up to $585 million in milestones.

Cencora’s associate director of value and access strategy for its commercialization strategy & access solutions division discusses the current state of pre-approval information exchanges.

The latest news for pharma industry insiders.

Inizio’s chief operations officer discusses how pharmaceutical companies are tailoring their product launch strategies to meet the diverse needs of stakeholders.

In an interview with Pharm Exec Associate Editor Don Tracy, Robert Zirkelback, Chief Public Affairs Officer, Head of Strategic Initiatives, PhRMA discusses best-case scenarios for health policy amid the 2024 presidential election.

In an interview with Pharm Exec Associate Editor Don Tracy, Carmen Villar, VP, ESG & Corporate Citizenship, Gilead Sciences discusses new skills that members of generation Alpha will bring to the pharma industry and potential struggles that they may face.

Companies offering post-grad rotational programs develop broad skillsets in new hires.

Moving forward, Durect plans on incorporating feedback from the FDA in the design of a Phase III trial.

The latest news for pharma industry insiders.

In an interview with Pharm Exec Associate Editor Don Tracy, Tala Fakhouri, at Financial Times’ US Pharma and Biotech Summit, Tala Fakhouri, Associate Director for Policy Analysis, FDA, discusses whether the FDA plans on restricting the use of AI and what the future could look like when it comes to machine learning.

Approval of Yesafili represents Biocon’s entrance into the US ophthalmology market, following previous approvals in Europe and the UK.

Experts discuss how new innovations are changing the relationship the industry has with patients.

The latest news for pharma industry insiders.

Experts discuss how attempts to solve the drug pricing problem in the US are working.

In an interview with Pharm Exec Associate Editor Don Tracy, Robert Zirkelback, Chief Public Affairs Officer, Head of Strategic Initiatives, PhRMA discusses the upcoming United States presidential election and the potential impact that it could have on the pharma industry.

Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) aims to support the development of Coya 302, a therapeutic candidate for the treatment of frontotemporal dementia (FTD).

The latest news for pharma industry insiders.

Experts discuss how the upcoming election is impacting the pharma industry, and how either party’s victory could change the landscape in the following years.

KOLs in the sector examine the current dealmaking landscape, including the status of available capital.